CE Marking Approval and First Implants of MRI Pacing Leads Announced
|
By MedImaging International staff writers Posted on 02 Apr 2014 |
|
Image: The Ingevity range is a comprehensive set of leads that can be placed using a 6 French introducer, including passive and active fixation models (Photo courtesy of Boston Scientific).
A range of magnetic resonance imaging (MRI)-compatible pacing leads has received the European CE marking, and the company that developed the leads recently announced the European market launch.
The Ingevity range, developed by Boston Scientific Corp. (Natick, MA, USA), are a comprehensive set of leads that can be placed using a 6 French introducer, including passive and active fixation models. Ingevity MRI pacing leads are part of the ImageReady MR-conditional pacemaker system, which includes Vitalio MRI, FormioMRI, AdvantioMRI, and Ingenio MRI pulse generators. When used with the Lattitude NXT patient management system, these devices wirelessly monitor patients for conditions such as atrial arrhythmias.
The first implant of the Ingevity MRI lead was performed on March 3, 2014, by Daniel Gras, MD, at the Nouvelles Cliniques Nantaises. “The Ingevity MRI lead offers exceptional handling and placement within the heart,” said Dr. Gras. “In addition, the Boston Scientific ImageReady pacing system could help many patients who may require an MRI scan during their life.”
“The Ingevity MRI pacing leads platform represents a significant milestone in our bradycardia technology and CRM lead portfolio,” said Michael Onuscheck, senior vice president and president, Boston Scientific Europe. “We are proud to offer multiple, new and innovative CRM leads engineered for superior long-term clinical performance, including Ingevity MRI pacing leads, Reliance 4-Front defibrillation leads, and the Acuity X4 CRT family of leads.”
One of the first implants of the Autogen X4 CRT-D system integrating all three of these new leads was performed by Dr. Gianluca Botto, head of cardiac electrophysiology and pacing at Sant'Anna Hospital (Como, Italy).
The subset of data from the Ingevity trial supporting CE marking approval demonstrated excellent performance including positive ratings on lead handling and maneuverability from 99.5% of implanters. The Ingevity trial series includes prospective, nonrandomized, multicenter, global clinical studies to support the Ingevity range of leads for CE marking, US Food and Drug Administration (FDA) and other regulatory approvals. Over 1600 patients have been implanted at 78 centers in 16 countries.
Ingevity MRI, Reliance 4-Front, Acuity X4, and Autogen X4 CRT-D are investigational devices and not yet available for sale in the United States.
Related Links:
Boston Scientific
The Ingevity range, developed by Boston Scientific Corp. (Natick, MA, USA), are a comprehensive set of leads that can be placed using a 6 French introducer, including passive and active fixation models. Ingevity MRI pacing leads are part of the ImageReady MR-conditional pacemaker system, which includes Vitalio MRI, FormioMRI, AdvantioMRI, and Ingenio MRI pulse generators. When used with the Lattitude NXT patient management system, these devices wirelessly monitor patients for conditions such as atrial arrhythmias.
The first implant of the Ingevity MRI lead was performed on March 3, 2014, by Daniel Gras, MD, at the Nouvelles Cliniques Nantaises. “The Ingevity MRI lead offers exceptional handling and placement within the heart,” said Dr. Gras. “In addition, the Boston Scientific ImageReady pacing system could help many patients who may require an MRI scan during their life.”
“The Ingevity MRI pacing leads platform represents a significant milestone in our bradycardia technology and CRM lead portfolio,” said Michael Onuscheck, senior vice president and president, Boston Scientific Europe. “We are proud to offer multiple, new and innovative CRM leads engineered for superior long-term clinical performance, including Ingevity MRI pacing leads, Reliance 4-Front defibrillation leads, and the Acuity X4 CRT family of leads.”
One of the first implants of the Autogen X4 CRT-D system integrating all three of these new leads was performed by Dr. Gianluca Botto, head of cardiac electrophysiology and pacing at Sant'Anna Hospital (Como, Italy).
The subset of data from the Ingevity trial supporting CE marking approval demonstrated excellent performance including positive ratings on lead handling and maneuverability from 99.5% of implanters. The Ingevity trial series includes prospective, nonrandomized, multicenter, global clinical studies to support the Ingevity range of leads for CE marking, US Food and Drug Administration (FDA) and other regulatory approvals. Over 1600 patients have been implanted at 78 centers in 16 countries.
Ingevity MRI, Reliance 4-Front, Acuity X4, and Autogen X4 CRT-D are investigational devices and not yet available for sale in the United States.
Related Links:
Boston Scientific
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ceiling-Mounted Digital Radiography System
Radiography 5000 C
New
X-Ray QA Meter
Piranha CT
New
Color Doppler Ultrasound System
KC20
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
Channels
Radiography
view channel
Novel Breast Imaging System Proves As Effective As Mammography
Breast cancer remains the most frequently diagnosed cancer among women. It is projected that one in eight women will be diagnosed with breast cancer during her lifetime, and one in 42 women who turn 50... Read more
AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
Radiologists typically detect one case of cancer for every 200 mammograms reviewed. However, these evaluations often result in false positives, leading to unnecessary patient recalls for additional testing,... Read more
Ultrasound
view channel.jpg "Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)")
Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease
Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more
Super-Resolution Imaging Technique Could Improve Evaluation of Cardiac Conditions
The heart depends on efficient blood circulation to pump blood throughout the body, delivering oxygen to tissues and removing carbon dioxide and waste. Yet, when heart vessels are damaged, it can disrupt... Read more
First AI-Powered POC Ultrasound Diagnostic Solution Helps Prioritize Cases Based On Severity
Ultrasound scans are essential for identifying and diagnosing various medical conditions, but often, patients must wait weeks or months for results due to a shortage of qualified medical professionals... Read more
Nuclear Medicine
view channel
New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more![Image: Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration (Photo courtesy of SNMMI)](https://globetechcdn.com/mobile_medicalimaging/images/stories/articles/article_images/2024-05-09/JNM May 2024 Hofman.jpg "Image: Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration (Photo courtesy of SNMMI)"){kind=small}
New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
Clear cell renal cell cancer (ccRCC) represents 70-80% of renal cell carcinoma cases. While localized disease can be effectively treated with surgery and ablative therapies, one-third of patients either... Read more
New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
Imaging inflammation using traditional radiological techniques presents significant challenges, including radiation exposure, poor image quality, high costs, and invasive procedures. Now, new contrast... Read more
New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read moreGeneral/Advanced Imaging
view channel
Bone Density Test Uses Existing CT Images to Predict Fractures
Osteoporotic fractures are not only devastating and deadly, especially hip fractures, but also impose significant costs. They rank among the top chronic diseases in terms of disability-adjusted life years... Read more
AI Predicts Cardiac Risk and Mortality from Routine Chest CT Scans
Heart disease remains the leading cause of death and is largely preventable, yet many individuals are unaware of their risk until it becomes severe. Early detection through screening can reveal heart issues,... Read more
Imaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Industry News
view channel
Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
Hologic, Inc. (Marlborough, MA, USA) has entered into a definitive agreement to acquire Endomagnetics Ltd. (Cambridge, UK), a privately held developer of breast cancer surgery technologies, for approximately... Read more
Bayer and Google Partner on New AI Product for Radiologists
Medical imaging data comprises around 90% of all healthcare data, and it is a highly complex and rich clinical data modality and serves as a vital tool for diagnosing patients. Each year, billions of medical... Read more
